Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose vs standard-dose quadrivalent influenza vaccine in children 6-35 months
NCT04544267Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Sep 2020
- Primary completion
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of quadrivalent influenza vaccine in influenza (2 arms), sponsored by Sanofi. Primary endpoint: Number of Participants With Laboratory-Confirmed Influenza Illness Caused by Any Influenza Viral Types/Subtypes. Started Sep 2020; status: terminated.
02
Drugs
quadrivalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04544267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04544267.